Literature DB >> 12871376

Role of P-selectin, beta2-integrins, and Src tyrosine kinases in mouse neutrophil-platelet adhesion.

V Evangelista1, S Manarini, B S Coller, S S Smyth.   

Abstract

BACKGROUND: The initial interaction of human polymorphonuclear leukocytes (PMN) with activated human platelets is mediated by P-selectin and its leukocyte ligand PSGL-1; subsequently the interaction is strengthened by activation of alphaMbeta2 via protein tyrosine phosphorylation mediated by Src kinases and binding of activated alphaMbeta2 to its platelet counterreceptor(s).
OBJECTIVES: Because mouse models are being used to define the role of PMN-platelet interactions in thrombosis and the response to vascular injury, we investigated the molecular determinants responsible for the interaction of murine PMNs with activated murine platelets.
METHODS: Mouse platelets were labeled with the green fluorescent dye BCECF and then activated with thrombin and fixed with 1% paraformaldehyde. Mouse PMNs were labeled with the red fluorescent dye hydroethidine and then stirred with the fixed platelets. After stopping the reaction with paraformaldehyde, formation of mixed cell conjugates was analyzed by flow cytometry.
RESULTS: In time course experiments, 90 +/- 1.9% of PMNs formed mixed conjugates with platelets after 2 min and the mean (+/- SEM) number of platelets per positive PMN was 8.4 +/- 1.5. A monoclonal antibody to P-selectin reduced the percentage of PMNs with attached platelets to 16 +/- 2.4% (P = 0.001), and only 8 +/- 5% of PMNs interacted with platelets from P-selectin-/- mice. In contrast, monoclonal antibodies to PSGL-1, beta2-integrin, and alphaIIbbeta3 had much less or no effect on the production of mixed cell aggregates. To better identify a secondary contribution of beta2-integrins, P-selectin interactions were disrupted by briefly adding 5 mm EGTA to already-formed mixed cell aggregates. Brief EGTA treatment alone reduced the percentage of PMNs with attached platelets to 70 +/- 3.5% (P = 0.004 vs. no treatment), but did not modify the number of platelets per positive PMN (9.5 +/- 1.7). The combination of brief EGTA treatment and a monoclonal antibody to beta2-integrin lowered the percentage of PMN with attached platelets to 50 +/- 7% and reduced the number of platelets attached per positive PMN to 3.6 +/- 0.7 (P = 0.03 vs. brief EGTA treatment only). Brief EGTA treatment did not modify the effect of the other antibodies. When the incubation was stopped with EGTA the Src inhibitors PP1 and PP2 reduced PMN-platelet adhesion, while the inactive analog PP3 was ineffective.
CONCLUSIONS: These results confirm that P-selectin plays a prominent role in mediating the initial interactions between mouse PMN and platelets, and provide support for additional contributions from beta2-integrins and Src family kinases.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12871376     DOI: 10.1046/j.1538-7836.2003.00214.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  12 in total

1.  Src family kinases mediate neutrophil adhesion to adherent platelets.

Authors:  Virgilio Evangelista; Zehra Pamuklar; Antonio Piccoli; Stefano Manarini; Giuseppe Dell'elba; Romina Pecce; Nicola Martelli; Lorenzo Federico; Mauricio Rojas; Giorgio Berton; Clifford A Lowell; Licia Totani; Susan S Smyth
Journal:  Blood       Date:  2006-11-09       Impact factor: 22.113

Review 2.  Selectins: initiators of leucocyte adhesion and signalling at the vascular wall.

Authors:  Rodger P McEver
Journal:  Cardiovasc Res       Date:  2015-05-20       Impact factor: 10.787

Review 3.  Integrin signaling in atherosclerosis.

Authors:  Alexandra C Finney; Karen Y Stokes; Christopher B Pattillo; A Wayne Orr
Journal:  Cell Mol Life Sci       Date:  2017-02-28       Impact factor: 9.261

Review 4.  Hydroethidine- and MitoSOX-derived red fluorescence is not a reliable indicator of intracellular superoxide formation: another inconvenient truth.

Authors:  Jacek Zielonka; B Kalyanaraman
Journal:  Free Radic Biol Med       Date:  2010-01-29       Impact factor: 7.376

5.  JAK2-V617F promotes venous thrombosis through β1/β2 integrin activation.

Authors:  Bärbel Edelmann; Nibedita Gupta; Tina M Schnoeder; Anja M Oelschlegel; Khurrum Shahzad; Jürgen Goldschmidt; Lars Philipsen; Soenke Weinert; Aniket Ghosh; Felix C Saalfeld; Subbaiah Chary Nimmagadda; Peter Müller; Rüdiger Braun-Dullaeus; Juliane Mohr; Denise Wolleschak; Stefanie Kliche; Holger Amthauer; Florian H Heidel; Burkhart Schraven; Berend Isermann; Andreas J Müller; Thomas Fischer
Journal:  J Clin Invest       Date:  2018-07-19       Impact factor: 14.808

Review 6.  Targeting P-selectin glycoprotein ligand-1/P-selectin interactions as a novel therapy for metabolic syndrome.

Authors:  Madhukar S Patel; David Miranda-Nieves; Jiaxuan Chen; Carolyn A Haller; Elliot L Chaikof
Journal:  Transl Res       Date:  2016-12-09       Impact factor: 7.012

7.  Microfluidic devices for studies of shear-dependent platelet adhesion.

Authors:  Edgar Gutierrez; Brian G Petrich; Sanford J Shattil; Mark H Ginsberg; Alex Groisman; Ana Kasirer-Friede
Journal:  Lab Chip       Date:  2008-07-23       Impact factor: 6.799

8.  Characterization of human platelet binding of recombinant T cell receptor ligand.

Authors:  Asako Itakura; Joseph E Aslan; Sushmita Sinha; Tara C White-Adams; Ishan A Patel; Roberto Meza-Romero; Arthur A Vandenbark; Gregory G Burrows; Halina Offner; Owen Jt McCarty
Journal:  J Neuroinflammation       Date:  2010-11-08       Impact factor: 8.322

9.  Src blockade stabilizes a Flk/cadherin complex, reducing edema and tissue injury following myocardial infarction.

Authors:  Sara Weis; Satoshi Shintani; Alberto Weber; Rudolf Kirchmair; Malcolm Wood; Adrianna Cravens; Heather McSharry; Atsushi Iwakura; Young-Sup Yoon; Nathan Himes; Deborah Burstein; John Doukas; Richard Soll; Douglas Losordo; David Cheresh
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 10.  The Neutrophil's Choice: Phagocytose vs Make Neutrophil Extracellular Traps.

Authors:  Angelo A Manfredi; Giuseppe A Ramirez; Patrizia Rovere-Querini; Norma Maugeri
Journal:  Front Immunol       Date:  2018-02-20       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.